Combined protective effect of an immunostimulatory bacterial preparation and rimantadine in experimental influenza A virus infection.

The protective effect of an immunostimulatory bacterial preparation, cytoplasmic membranes of Escherichia coli WF stable protoplast type L-forms (CM) alone and in combination with the selective antiviral drug rimantadine was evaluated in experimental influenza A/Aichi/2/68 (H3N2) virus infection in mice. In sublethal infection, CM administered intraperitoneally (i.p.) 7 days before virus exposure in a single dose of 25 mg/kg did not reduce significantly the virus lung titers. In lethal infection, CM applied in the same way weakly reduced the mortality rate. The combined application of CM with rimantadine resulted in synergistically increased protection, determined on the basis of virus lung titers, lung consolidation, mortality rates, protective indices, and survival times.
AuthorsJ Serkedjieva, E Ivanova
JournalActa virologica (Acta Virol) Vol. 41 Issue 2 Pg. 65-70 (Apr 1997) ISSN: 0001-723X [Print] CZECH REPUBLIC
PMID9219635 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Immunologic
  • Rimantadine
  • Adjuvants, Immunologic (therapeutic use)
  • Animals
  • Escherichia coli (immunology)
  • Female
  • Influenza A virus (immunology, pathogenicity)
  • Male
  • Mice
  • Orthomyxoviridae Infections (therapy)
  • Rimantadine (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: